These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 25819125)
1. [Management of side effects of targeted therapies in renal cancer: cutaneous side effects]. Robert C; Gimel P Bull Cancer; 2011; 98(3 Suppl):S35-46. PubMed ID: 25819125 [TBL] [Abstract][Full Text] [Related]
2. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338 [TBL] [Abstract][Full Text] [Related]
3. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Schmidinger M; Bellmunt J Cancer Treat Rev; 2010 Aug; 36(5):416-24. PubMed ID: 20163917 [TBL] [Abstract][Full Text] [Related]
4. Targeted therapy and hand-foot skin reaction in advanced renal cell carcinoma. Yang CH; Chuang CK; Hsieh JJ; Chang JW Expert Opin Drug Saf; 2010 May; 9(3):459-70. PubMed ID: 20113155 [TBL] [Abstract][Full Text] [Related]
5. [Management of side effects of targeted therapies in renal cancer: iatrogenic side effects]. Massard C; Patard JJ; Hermine O; Ravaud A Bull Cancer; 2011; 98(3 Suppl):S79-94. PubMed ID: 25819130 [TBL] [Abstract][Full Text] [Related]
6. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Autier J; Escudier B; Wechsler J; Spatz A; Robert C Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy. Reyes-Habito CM; Roh EK J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801 [TBL] [Abstract][Full Text] [Related]
8. Pazopanib for the treatment of renal cancer. Al-Marrawi MY; Rini B Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066 [TBL] [Abstract][Full Text] [Related]
9. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma. Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550 [TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for renal cell cancer: current perspectives. van der Veldt AA; Haanen JB; van den Eertwegh AJ; Boven E Discov Med; 2010 Nov; 10(54):394-405. PubMed ID: 21122471 [TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways. Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339 [TBL] [Abstract][Full Text] [Related]
12. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Ainsworth NL; Lee JS; Eisen T Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291 [TBL] [Abstract][Full Text] [Related]
13. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence. Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289 [TBL] [Abstract][Full Text] [Related]
14. Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Agarwala SS; Case S Oncologist; 2010; 15(3):236-45. PubMed ID: 20215359 [TBL] [Abstract][Full Text] [Related]